147 related articles for article (PubMed ID: 31402121)
1. Neuro-regeneration Therapeutic for Alzheimer's Dementia: Perspectives on Neurotrophic Activity.
Sun MK; Alkon DL
Trends Pharmacol Sci; 2019 Sep; 40(9):655-668. PubMed ID: 31402121
[TBL] [Abstract][Full Text] [Related]
2. Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss.
Ager RR; Davis JL; Agazaryan A; Benavente F; Poon WW; LaFerla FM; Blurton-Jones M
Hippocampus; 2015 Jul; 25(7):813-26. PubMed ID: 25530343
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
4. Synaptic Plasticity, Dementia and Alzheimer Disease.
Skaper SD; Facci L; Zusso M; Giusti P
CNS Neurol Disord Drug Targets; 2017; 16(3):220-233. PubMed ID: 28088900
[TBL] [Abstract][Full Text] [Related]
5. Beta-amyloid, neuronal death and Alzheimer's disease.
Carter J; Lippa CF
Curr Mol Med; 2001 Dec; 1(6):733-7. PubMed ID: 11899259
[TBL] [Abstract][Full Text] [Related]
6. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.
Kazim SF; Blanchard J; Dai CL; Tung YC; LaFerla FM; Iqbal IG; Iqbal K
Neurobiol Dis; 2014 Nov; 71():110-30. PubMed ID: 25046994
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies.
Pereira C; Agostinho P; Moreira PI; Cardoso SM; Oliveira CR
Curr Drug Targets CNS Neurol Disord; 2005 Aug; 4(4):383-403. PubMed ID: 16101556
[TBL] [Abstract][Full Text] [Related]
9. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid.
Nimmrich V; Ebert U
Rev Neurosci; 2009; 20(1):1-12. PubMed ID: 19526730
[TBL] [Abstract][Full Text] [Related]
10. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.
Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ
Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172
[TBL] [Abstract][Full Text] [Related]
11. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
Tomiyama T
Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease.
Turner RS
Semin Neurol; 2006 Nov; 26(5):499-506. PubMed ID: 17048151
[TBL] [Abstract][Full Text] [Related]
13. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.
Shin MK; Kim HG; Baek SH; Jung WR; Park DI; Park JS; Jo DG; Kim KL
Neurobiol Aging; 2014 May; 35(5):990-1001. PubMed ID: 24268884
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Neurodegeneration: Integrating Photobiomodulation and Neurofeedback in Alzheimer's Dementia and Parkinson's: A Review.
Berman MH; Nichols TW
Photobiomodul Photomed Laser Surg; 2019 Oct; 37(10):623-634. PubMed ID: 31647776
[No Abstract] [Full Text] [Related]
15. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.
Berg L; McKeel DW; Miller JP; Storandt M; Rubin EH; Morris JC; Baty J; Coats M; Norton J; Goate AM; Price JL; Gearing M; Mirra SS; Saunders AM
Arch Neurol; 1998 Mar; 55(3):326-35. PubMed ID: 9520006
[TBL] [Abstract][Full Text] [Related]
16. Neurodegeneration and Neuro-Regeneration-Alzheimer's Disease and Stem Cell Therapy.
Vasic V; Barth K; Schmidt MHH
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480448
[TBL] [Abstract][Full Text] [Related]
17. The basis for disease-modifying treatments for Alzheimer's disease: the Sixth Annual Mild Cognitive Impairment Symposium.
Duara R; Barker W; Loewenstein D; Bain L
Alzheimers Dement; 2009 Jan; 5(1):66-74. PubMed ID: 19118811
[TBL] [Abstract][Full Text] [Related]
18. The Role of Lysosomes in a Broad Disease-Modifying Approach Evaluated across Transgenic Mouse Models of Alzheimer's Disease and Parkinson's Disease and Models of Mild Cognitive Impairment.
Hwang J; Estick CM; Ikonne US; Butler D; Pait MC; Elliott LH; Ruiz S; Smith K; Rentschler KM; Mundell C; Almeida MF; Stumbling Bear N; Locklear JP; Abumohsen Y; Ivey CM; Farizatto KLG; Bahr BA
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31505809
[TBL] [Abstract][Full Text] [Related]
19. A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.
Luo J; Lee SH; VandeVrede L; Qin Z; Ben Aissa M; Larson J; Teich AF; Arancio O; D'Souza Y; Elharram A; Koster K; Tai LM; LaDu MJ; Bennett BM; Thatcher GR
Mol Neurodegener; 2016 Apr; 11():35. PubMed ID: 27129593
[TBL] [Abstract][Full Text] [Related]
20. Synaptic Compensation as a Probable Cause of Prolonged Mild Cognitive Impairment in Alzheimer's Disease: Implications from a Transgenic Mouse Model of the Disease.
Baazaoui N; Flory M; Iqbal K
J Alzheimers Dis; 2017; 56(4):1385-1401. PubMed ID: 28222506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
